The circadian gene Dec2 promotes pancreatic cancer dormancy by regulating tumor cell antigen presentation to facilitate immune evasion

Chris R Harris,Lan Wang,Crissy Dudgeon,Orjola Prela,Juliana Cazarin de Menezes,Ching-Hua Shih,Christina Davidson,Anthony Casabianca,Subhajyoti De,Wade Narrow,Jennifer Becker,Vinod Balachandran,Paul Grandgenett,Jean Grem,Michael A Hollingsworth,Minsoo Kim,Yeonsun Hong,Scott A. Gerber,Paula M Vertino,ChongFeng Gao,Anna Repesh,Zachary Klamer,Yansheng Hao,Brian J. Altman,Brian B. Haab,Darren R Carpizo
DOI: https://doi.org/10.1101/2024.11.12.623005
2024-11-15
Abstract:Summary The mechanisms that regulate cancer dormancy remain poorly understood. Using a mouse model of resectable pancreatic adenocarcinoma (PDAC), we identified Dec2 as a gene that was upregulated in metastatic dormant tumor cells. Deletion of Dec2 from tumor cells substantially increased mouse survival after resection due to an immune-mediated mechanism as the survival benefit was abrogated in immunodeficient conditions. Dec2 promoted immune evasion by repressing multiple components of the MHC-I dependent antigen presentation pathway in tumor cells. Dec2 is a regulator of circadian rhythms, and we found several components of the antigen presentation pathway oscillated in a circadian manner that was lost upon deletion of Dec2. Moreover, T-cell mediated tumor cell killing varied depending on the time of day. We suggest that lowered MHC-I presentation of antigens during rest phase is a natural effect of the circadian clock, which is exploited by Dec2-overexpressing pancreatic tumors to evade the immune system.
Cancer Biology
What problem does this paper attempt to address?